Stereoselective synthesis of a MCHr1 antagonist

Journal of Organic Chemistry

Volumn 72, Issue 25, 2007, Pages 9648-9655

  Andersen, Denise ^a   Storz, Thomas ^a,d   Liu, Pingli ^b   Wang, Xin ^a   Li, Leping ^a   Fan, Pingchen ^a   Chen, Xiaoqi ^a   Allgeier, Alan ^a   Burgos, Alain ^c   Tedrow, Jason ^a   Baum, Jean ^a   Chen, Ying ^a   Crockett, Rich ^a   Huang, Liang ^a   Syed, Rashid ^a   Larsen, Robert D ^a   Martinelli, Mike ^a  

^a AMGEN INC   (United States)

^b Process Chemistry   (United States)

^c La Croix Cadeau   (France)

^d WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLPIPERIDONE; DIASTEREOMERS; MELANIN-CONCENTRATING HORMONE (MCH); STEREOSELECTIVE SYNTHESIS;

HYDROGENATION; MAMMALS; STEREOSELECTIVITY; SYNTHESIS (CHEMICAL);

HORMONES;

ALDEHYDE; AMG 076; HORMONE ANTAGONIST; HYDRAZINE; INDOLE; MELANIN CONCENTRATING HORMONE; PIPERIDINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINATION; ANNULATION REACTION; ARTICLE; DIASTEREOISOMER; DRUG POTENCY; DRUG SYNTHESIS; HYDROGENATION; LARGE SCALE PRODUCTION; OBESITY; STEREOCHEMISTRY;

BENZENESULFONATES; CYCLOHEXANECARBOXYLIC ACIDS; HUMANS; ISOQUINOLINES; MOLECULAR STRUCTURE; RECEPTORS, SOMATOSTATIN; STEREOISOMERISM;

EID: 36849056087     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo701894v     Document Type: Article

References (56)

1. (a) Cambers, J.; Ames, R. S.; Bergsma, D.; Muir, A.; Fitzgerald, L. R.; Hervieu, G.; Dytko, G. M.; Foley, J. J.; Martin, J.; Liu, W-S.; Park, J.; Ellis, C.; Ganguly, S.; Konchar, S.; Cluderays, J.; Leslie, R.; Wilson, S.; Sarau, H. M. Nature 1999, 400, 261.
2. (b) Saito, Y.; Nothacker, H-P.; Wang, Z.; Lin, S.; Leslie, F.; Civelli, O. Nature 1999, 400, 265.
3. (a) Gomori, A.; Ishihara, A.; Ito, M.; Mashiko, S.; Matsushita, H.; Yumoto, M.; Tananka, T.; Tokita, S.; Moriya, M.; Iwassa, H.; Kanatani, A. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E583.
4. (b) Ito, M.; Gomori, A.; Ishihara, A.; Oda, Z.; Mashiko, S.; Natsushita, H.; Yumoto, M.; Sano, H.; Moriya, M.; Kanatani, A. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E940.
5. (c) Kennedy, A. R.; Todd, J. F.; Stanley, S. A.; Abbott, C. R.; Small, C. J.; Ghateri, M. A.; Bloom, S. R. Endocrinology 2001, 742, 3265.
6. (d) Sherman, L. P.; Camacho, R. E.; Sloan, S. D.; Zhou, Bednarek, M. A.; Hereniuk, D. L.; Feighner, S. D.; Tan, C. P.; Howard, A. D.; Van der Ploeg, L. H.; MacIntyre, D. E.; Hickey, G. J.; Strack, A. M. Eur. J. Pharmacol. 2003, 15, 475.
7. (a) Shimada, M.; Tritos, D.; Aitken, A.; Donella-Deana, A.; Hemmings, B. A.; Parker, P. J. Nature 1998, 396, 670.
8. (b) Shimada, M.; Tritos, D.; Aitken, A.; Donella-Deana, A.; Hemmings, B. A.; Parker, P. J. Eur. J. Biochem. 1982, 724, 21.
9. (c) Chen, Y.; Hu, C.; Hsu, C. K.; Zhang, Q.; Bi, C.; Asnicar, M.; Hsiung, H. M.; Fox, N.; Slieker, L. J.; Yang, D. D.; Heiman, M. L.; Shi, Y. Endocrinology 2002, 143, 2469.
10. (d) Marsh, D. J.; Weingarth, D. T.; Novi, D. E.; Chen, H. Y.; Trumbauer, M. E.; Chen, A. S.; Guan, X. M.; Jiang, M. M.; Feng, Y.; Camacho, R. E.; Shen, Z.; Frazier, E. G.; Yu, H.; Metzger, J. M.; Kuca, S. J.; Shearman, L. P.; Gopal-Truter, S.; Macneil, D. J.; Strack, A. M.; MacIntntyre, D. E.; Van der Ploeg, L. H.; Qian, S. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 3240.
11. (a) Tavares, F. X.; Al-Barazanji, K. A.; Bishop, M. J.; Britt, C. S.; Carlton, D. L.; Cooper, J. P.; Feldman, P. L.; Garrido, D. M.; Goertz, A. S.; Grizzle, M. K.; Hertzog, D. L.; Ignar, D. M.; Lang, D. G.; McIntryre, M. S.; Ott, R. J.; Peat, A. J.; Zhou, H.-Q. J. Med. Chem. 2006, 49, 7108.
12. (b) Tavares, F. X.; Al-Barazanji, K. A.; Bigham, E. C.; Bishop, M. J.; Britt, C. S.; Carlton, D. L.; Feldman, P. L.; Goertz, A. S.; Grizzle, M. K.; Guo, Y. C.; Handlon, A. L.; Hertzog, D. L.; Ignar, D. M.; Lang, D. G.; Ott, R. J.; Peat, A. J.; Zhou, H.-Q. J. Med. Chem. 2006, 49, 7095.
13. (c) Takekawa, S.; Asami, A.; Ishihara, Y.; Terauchi, J.; Kato, K.; Shimomura, Y.; Mori, M.; Murakoshi, H.; Kato, K.; Suzuki, N.; Nishimura, O.; Fujino, M. Eur. J. Pharmacol. 2002, 483, 129.
14. (d) Kowalski, T. J.; Farley, C.; Cohen-Williams, M. E.; Varty, G.; Spar, B. D. Eur. J. Pharmacol. 2004, 497, 41.
15. (e) Borowsky, B.; Durkin, M. M.; Ogozalek, K.; Marzabadi, M. R.; DeLeon, J.; Lagu, B. Nat. Med. 2002, 8, 825.
16. (f) Arienzo, R.; Clack, D. E.; Cramp, S.; Daly, S.; Dyke, H. J.; Lockey, P.; Norman, D.; Roach, A. G.; Stuttle, K.; Tomlinson, M.; Wong, M.; Wren, S. P. Bioorg. Med. Chem. Lett. 2004, 14, 4099.
17. (g) Clark, D. E.; Higgs, C.; Wren, S. P.; Dyke, H. J.; Wong, M.; Norman, D.; Lockey, P.; Roach, A. G. J. Med. Chem. 2004, 47, 3962.
18. (h) Souers, A. J.; Wodka, D.; Gao, J.; Lewis, J. C.; Vasudevan, A.; Gentles, R.; Brodjian, S.; Dayton, B.; Ogiela, C. A.; Collins, C. A.; Kym, P. R. Bioorg. Med. Chem. Lett. 2004, 14, 4879.
19. (i) Souers, A. J.; Wodka, D.; Gao, J.; Lewis, J. C.; Vasudevan, A.; Brodjian, S.; Dayton, B.; Ogiels, C. A.; Fry, D.; Hernandez, L. E.; Marsh, K. C.; Collins, C. A.; Kym, P. R. Bioorg. Med. Chem. Lett. 2004, 14, 4883.
20. (j) Ulven, T.; Frimurer, T. M.; Receveur, J.-M.; Little, P. B.; Rist, O.; Norregaard, P. K.; Hogberg, T. J. Med. Chem. 2005, 48, 5684.
21. (k) Soures, A. J.; Gao, J.; Brune, M.; Bush, E.; Wodka, D.; Vasudevan, A.; Dayton, B.; Shapiro, R.; Hernandez, L. E.; Collins, C. A.; Kym, P. R. J. Med. Chem. 2005, 48, 1318.
22. (a) Leping, L; Fan, P.; Chen, X; Mihalic, J.; Fu, Y.; Dai, K.; Liang, L.; Reed, M.; Wright, M.; Timmermans, P.; Chen, J-L.; Laen, J. Abstracts of Papers, 231st National Meeting of the American Chemical Society, March 26-30, 2006; American Chemical Society: Washington, DC, 2006.
23. (b) Chen, X.; Chen, X.; Fan, P.; Jaen, J.; Li, L.; Mihalic, J. T. Patent WO 04/043958 A1, 2004.
24. For an alternative strategy for the formation of a similar, tetracyclic isoquinolinone system, see: Le Goffic, F.; Gouyetts, A.; Ahoud, A. Tetrahedron 1973, 29, 3357.
25. Gawley, R. E. Synthesis 1976, 777.
26. Annulation of N-methyl-4-piperidone with pentenone was reported to give the N-Me analogue of 9. However, the stereochemistry was not defined, see: (a) Bergman, J.; Goonewardena, H. Acta. Chem. Scand. Ser. B 1980, 34, 763.
27. For the reaction of 2-methylcyclohexanones with pentenone, see: (b) Kikughi, M.; Yoshikoshi, A. Bull. Chem. Soc. Jpn. 1981, 54, 3420.
28. (c) Coates, R. M.; Shaw, J. E. J. Am. Chem. Soc. 1970, 92, 5657.
29. Robinson annulation of cyclohexanone with β-aryl methyl vinyl ketones has been reported but the stereochemistry was not defined, see: (d) Eiden, F.; Gmeiner, P. Arch. Pharm. 1988, 321, 397.
30. (e) Eiden, F.; Gmeiner, P. Liebigs Ann. Chem. 1988, 125.
31. (a) Djerassi, C.; Pettit, G. R. J. Org. Chem. 1957, 22, 393.
32. (b) Danishefsky, S.; Cavanaugh, R. J. Org. Chem. 1968, 33, 2959.
33. (c) The reaction was monitored by gas chromatography for the consumption of N-benzyl-4-piperidone. It was critical to the success of this process to leave <2.5% of the starting material at this stage.
34. 1H NMR. It was essential to check the quality of the 3-penten-2-one used carefully. A thorough analytical analysis revealed that it can contain variable amounts of acetic acid and water. These impurities caused hydrolysis of enamine 8, regenerating N-benzyl-4-piperidone, which lowered the yield of the tartrate salt dramatically. Experimentation revealed that <0.10 wt % of acetic acid and <1.0 wt % of water were tolerated.
35. The structures were surmised by the GC/MS and literature precedent, see: Stork, G.; Brizzolara, A.; Landesman, H.; Szmuskovicz, J.; Terrell, R. J. Am. Chem. Soc. 1963, 55, 207. All the intermediates were converted to the enone after addition of acetic acid.
36. The amount of piperidone was detrimental to the isolated yield of the tartrate salt of 9. With > 10% of N-benzyl-4-piperidone, the resolution yield of 9 dropped from 28% overall yield to <12%, and in some cases, the tartrate salt failed to crystallize. In the event that the N-benzyl-4-piperidone was outside the set specification, unreacted material could be removed by washing the crude enone mixture with 1 M aqueous citric acid at pH 5.4.
37. A second slurry in 80% ethanol/water could upgrade the material to 98.5% ee, if required. However, material of >96% ee will produce isoquinolinone 6 with >99% ee in the subsequent transformations.
38. 1H NMR. The remaining isomer 6c was not isolated. The structure of 6c was assumed based on the mass obtained from mass spectrometry and retention time comparison to the three characterized isomers 6, 6a, and 6b. The stereochemistry of the methyl group was key to the selectivity in the hydrogenation to produce the anti-relationship between me two bridgehead positions. For comparison, the des-methyl-N-benozyl analogue of 9 was converted to a mixture of the syn,anti-isomers: Rastogi, S. N.; Bindra, J. S.; Rai, S. N. Indian J. Chem. 1972, 10, 673.
39. Hughes, D. L. Org. Prep. Proced. Int. 1993, 25, 667.
40. Liazarzabura, M. E.; Shuttleworth, S. J. Tetrahedron Lett. 2004, 45, 4781.
41. The Fischer-indolization of analogous decalinone systems has been reported to be selective for the formation of the linear isomer over the angular isomer: (a) Miller, F. M.; Lohr, R. A., Jr. J. Am. Chem. Soc. 1978, 43, 3388.
42. (b) Rastogi, S. N.; Bindra, J. S.; Rai, S. N.; Anand, N. Indian J. Chem. 1972, 10, 673.
43. (c) Christoffers, J. Synthesis 2006, 318.
44. 3).
45. Chen, C.; Lieberman, D. R.; Larsen, R. D.; Verhoeven, T. R.; Reider, P. J. J. Org. Chem. 1997, 62, 2576.
46. Chandrasekaran, S.; Tuner, J. V. Synth. Commun. 1982, 12, 727.
47. The formaldehyde from the ozonolysis of compound 17 was not easily separated. Despite wiped-film distillation of aldehyde 3 [see: (a) Cvengroš, J.; Valko, M.; Pollák, S.; Lutišan, J. Chem. Papers 1999, 53, 417] small amounts of formaldehyde always contaminated the product, which over time produced other byproducts. Aldehyde 3 was also prone to air oxidation.
48. To improve stability, 1000 ppm of triefhanolamine [see: (b) Ishihara, T.; Yamamoto, A.; Ohshima, M.; Aiba, N. Patent EP 0148648.
49. (c) Weber, J.; Falk, V.; Kniep, C. Patent DE 2917789] was added to the distilled product, which was isolated in 78% yield and >95% purity as a light yellow oil. In contrast, no formaldehyde was generated in the ozonolysis of intermediate 18 to aldehyde 3. Material prepared from this route was free of side products and was isolated in >95% yield and >99% GC purity without the need for wiped-film distillation. As mentioned, one problem with using the aldehyde 3 derived from 17 was the presence of small amounts of formaldehyde. This led to me formation of the N-Me derivative 19. This impurity could be avoided by using 3 prepared from 18.
50. 3 prior to the reducing agent, acetal formation was prevented.
51. Direct alkylation of carboxylic acids has been reported previously: (a) Creger, P. L. J. Org. Chem. 1972, 37, 1907.
52. (b) Miller, R. D.; Goelitz, P. J. Org. Chem. 1981, 46, 1616.
53. For instance, see: (a) Sinhababu, A. K.; Borchardt, R. T. J. Org. Chem. 1983, 48, 2356.
54. (b) El-Shishtawy, R. M.; Fukunishi, K. Synthesis 1994, 1411.
55. (c) Tanino, H.; Fukuishi, K.; Ushiyama, M.; Okada, K. Tetrahedron 2004, 60, 3273.
56. Only alcohol solvents performed well in this reaction. The N-ethyl byproduct of 2 was observed in ethanol due to the generation of acetaldehyde from oxidation of the solvent. Fortunately, isopropanol resulted in <1% of the corresponding N-alkylated byproduct. In t-BuOH and sec-BuOH the reactions were prohibitively sluggish.